IFM Therapeutics' Acquisition

IFM Therapeutics was acquired by Bristol-Myers Squibb on August 03, 2017.

IFM Therapeutics is a biopharmaceutical company developing a portfolio of first-in-class small molecules targeting the innate immune system. IFM Therapeutics is developing modulators of novel targets …

Articles about IFM Therapeutics' Acquisition: